Review Article
Granich et al. Int J Virol AIDS 2018, 5:043 DOI: 10.23937/2469-567X/1510043 Volume 5 | Issue 1
A practical tool to help health workers in the clinical and operational management of multidrug-resistant tuberculosis with special focus on the introduction, implementation and management of the nine-month treatment regimen.
Good Manufacturing Practice (GMP) describes a set of principles and procedures that, when followed, ensure that medicines and related substances are of high quality, safety and efficacy. SAHPRA is a
participating authority of the Pharmaceutical Inspection Cooperation Scheme (jointly known as PIC/S).... PIC/S aims to develop international standards between countries and pharmaceutical inspection
authorities, to provide harmonised and constructive co-operation in the field of GMP. PIC/S affiliation is subject to initial and periodic assessment of the participating authority to ensure that it has equivalent legislation, regulatory and enforcement procedures and inspection capacity.
more
• provide scientific information on the safety, efficacy, and quality control/ quality assurance of widely used medicinal plants, in order to facilitate their appropriate use in Member States;
• provide models to assist Member States in developing their own mono- graphs or formularies for these... or other herbal medicines; and
• facilitate information exchange among Member States.
more
Pharmaceutical regulators are at the forefront of ensuring that only safe and effective medicines are authorized and available in the market. This document builds on the recommendations in the above publication and has been prepared to specifically assist national medicines regulatory authorities to... understand the nature and extent of oxytocin quality issues and to provide key technical information and quality requirements for oxytocin products in dossier assessments. Furthermore, this document also presents recommendations on other regulatory actions needed to ensure that only quality-assured oxytocin products are authorized and made available to women.
more
This document serves to provide interim guidance/ recommendations to carry out mpox surveillance activities mainly case investigation, contact tracing and isolation. For the development of this document WHO, UKHSA and CDC guidelines were referred to and adopted within the country context.
Цей документ описує кроки, необхідні для визначення скоригованого інтервалу QT (QTc) в
ході моніторингу ЕКГ пацієнтів, які отримують препарати для лікування ХР ТБ, що... викликають пролонгацію інтервалу QT. Він також надає рекомендації щодо ведення випадків пролонгації QTc.
more
Meeting report
Geneva, 16-18 November 2016
Shielding is a term used to describe the protection of individuals at high risk of severe COVID-19 illness by separating them from the general population.
The purpose of this document is to inform the public about biological and chemical hazards and thereby prepare the population for an immediate response in the event of an incident until public health support is provided.
The agents reported here are: Anthrax, Botulism, Haemorrhagic Fever,
...Smallpox, the Plague, Tularaemia, Chlorine, Cyanide, Lewisite, Mustard Gas,
Ricin, Sarin, Soman, Tabun and VX. This list is not exhaustive and no doubt
other dangerous types could be produced. They have been selected as they are the most often mentioned threats. This information has been prepared with the public in mind, and thus much of the medical terminology has been removed and replaced with every day language.
Also available in Arabic: http://www.who.int/csr/delibepidemics/biochem_threatsAR.pdf?ua=1
more
Cardiovascular disease is a major cause of disability and premature death throughout the world, and contributes substantially to the escalating costs of health care. The underlying pathology is atherosclerosis, which develops over many years and is usually advanced by the time symptoms occur, genera...lly in middle age. Acute coronary and cerebrovascular events frequently occur suddenly, and are often fatal before medical care can be given. Modification of risk factors has been shown to reduce mortality and morbidity in people with diagnosed or undiagnosed cardiovascular disease.
This publication provides guidance on reducing disability and premature deaths from coronary heart disease, cerebrovascular disease and peripheral vascular disease in people at high risk, who have not yet experienced a cardiovascular event. People with established cardiovascular disease are at very high risk of recurrent events and are not the subject of these guidelines. They have been addressed in previous WHO guidelines.
Several forms of therapy can prevent coronary, cerebral and peripheral vascular events. Decisions about whether to initiate specific preventive action, and with what degree of intensity, should be guided by estimation of the risk of any such vascular event. The risk prediction charts that accompany these guidelinesb allow treatment to be targeted accord-
ing to simple predictions of absolute cardiovascular risk.
Recommendations are made for management of major cardiovascular risk factors through changes in lifestyle and prophylactic drug therapies. The guidelines provide a framework for the development of national guidance on prevention of cardiovascular disease that takes into account the particular political, economic, social and medical circumstances.
more